number
import
human
infect
caus
positivestrand
rna
virus
yet
almost
none
treat
small
molecul
antivir
therapeut
one
except
chronic
infect
caus
hepat
c
viru
hcv
new
gener
potent
inhibitor
develop
one
main
molecular
target
antihcv
drug
viral
rnadepend
rna
polymeras
review
summar
search
nucleosid
nucleotid
analog
inhibit
hcv
led
fda
approv
sofosbuvir
advanc
antihcv
therapeut
also
stimul
effort
develop
nucleosid
analog
positivestrand
rna
virus
although
remain
valid
clinic
prospect
use
nucleosid
analog
treat
acut
infect
caus
rna
virus
repres
import
paradigm
shift
new
frontier
futur
antivir
therapi
inhibit
viral
rna
polymeras
nucleosid
nucleotid
analog
therapeut
applic
positivestrand
rna
virus
beyond
hepat
c
viru
jerom
deval
julian
symon
leo
beigelman
number
import
human
infect
caus
positivestrand
rna
virus
yet
almost
none
treat
small
molecul
antivir
therapeut
one
except
chronic
infect
caus
hepat
c
viru
hcv
new
gener
potent
inhibitor
develop
one
main
molecular
target
antihcv
drug
viral
rnadepend
rna
polymeras
review
summar
search
nucleosid
nucleotid
analog
inhibit
hcv
led
fda
approv
sofosbuvir
advanc
antihcv
therapeut
also
stimul
effort
develop
nucleosid
analog
positivestrand
rna
virus
although
remain
valid
clinic
prospect
use
nucleosid
analog
treat
acut
infect
caus
rna
virus
repres
import
paradigm
shift
new
frontier
futur
antivir
therapi
introduct
rna
polymeras
hcv
target
nucleosid
analog
hepat
c
viru
hcv
member
flavivirida
famili
virus
famili
contain
singlestrand
positivesens
rna
genom
kb
viral
genom
encod
one
openread
frame
translat
polyprotein
approxim
amino
acid
hcv
estim
infect
approxim
million
individu
worldwid
million
new
infect
occur
year
recent
treatment
option
chronic
hcv
infect
larg
suboptim
due
limit
efficaci
substanti
toxic
standard
care
soc
cours
pegyl
interferon
alpha
pegifna
combin
ribavirin
effect
clearanc
sustain
virolog
respons
svr
rate
viru
achiev
less
case
infect
preval
strain
hcv
unit
state
europ
sinc
two
inhibitor
viral
serin
proteas
boceprevir
telaprevir
approv
use
combin
pegifna
ribavirin
molecul
call
directact
antivir
daa
specif
bind
inhibit
viral
protein
requir
viru
replic
although
toxic
burden
newer
treatment
option
remain
high
svr
rate
presenc
proteas
inhibitor
improv
difficulttotreat
infect
daa
specif
block
hcv
enzymat
function
intens
studi
last
decad
polymeras
function
emerg
one
attract
target
next
gener
antihcv
therapi
hcv
protein
rnadepend
rna
polymeras
rdrp
requir
replic
viral
genom
synthesi
minusstrand
intermedi
transcript
level
synthesi
viral
mrna
rdrp
enzymat
activ
uniqu
virus
found
human
cell
make
attract
target
antivir
drug
develop
see
detail
review
structur
function
protein
compos
amino
acid
similar
known
rdrp
hcv
contain
six
conserv
motif
design
af
amino
acid
involv
catalyt
activ
locat
within
motif
aspart
posit
catalyt
triad
gdd
posit
motif
c
orient
residu
activ
site
contribut
catalyt
activ
support
crystal
structur
protein
use
polymeras
righthand
analog
model
hcv
protein
featur
finger
palm
thumb
subdomain
figur
unlik
tradit
openhand
conform
share
mani
dna
polymeras
hcv
featur
encircl
activ
site
due
extens
interact
finger
thumb
subdomain
contact
restrict
flexibl
subdomain
favor
first
step
initi
rna
synthesi
lead
format
primer
strand
therefor
import
structur
chang
involv
open
thumb
finger
requir
primer
extens
elong
step
anoth
uniqu
featur
bhairpin
loop
protrud
activ
site
locat
base
palm
subdomain
figur
amino
acid
loop
locat
within
thumb
residu
suggest
interfer
bind
doublestrand
rna
due
steric
hindranc
delet
allow
enzym
favor
primerdepend
rna
synthesi
result
truncat
protein
cocrystal
elong
mode
doublestrand
rna
primer
extens
also
requir
ctermin
part
move
away
catalyt
site
structur
featur
share
rna
polymeras
import
conform
chang
take
place
enzym
becom
process
effici
rna
synthesi
increas
consider
precis
elong
phase
rna
synthesi
hcv
inhibit
nucleotid
analog
act
chain
termin
figur
initi
major
class
nucleosid
analog
therapeut
potenti
demonstr
potent
inhibit
hcv
rna
polymeras
activ
cmethylribonucleosid
first
cmethyl
ribonucleosid
origin
synthes
later
cmethyluridin
triphosph
found
act
chain
termin
escherichia
coli
rna
polymeras
antivir
assay
cmethylcytidin
origin
describ
inhibitor
bovin
diarrhea
viru
bvdv
viru
close
relat
hcv
use
surrog
although
compound
highli
potent
select
tissu
cultur
low
bioavail
made
unsuit
oral
dose
limit
overcom
ad
lvalin
ester
group
oh
posit
sugar
figur
result
drug
valopicitabin
efficaci
dose
oral
hcvinfect
chimpanze
although
nucleosid
significantli
reduc
hcv
viral
load
patient
develop
discontinu
phase
ii
clinic
trial
due
doselimit
gastrointestin
gi
toxic
cmethyl
nucleosid
cmethyladenosin
report
inhibit
hcv
replic
none
evalu
clinic
trial
presum
due
tissu
retent
issu
preclin
speci
vitro
prolong
cultur
hcv
repliconcontain
hepatocyt
cmethylnucleosid
result
select
singl
mutat
within
result
polymeras
resist
class
nucleosid
second
class
antihcv
nucleosid
scaffold
molecul
class
resembl
azidothymidin
azt
origin
synthes
test
human
immunodefici
viru
compound
librari
screen
subgenom
replicon
assay
azidocytidin
later
identifi
potent
inhibitor
hcv
triphosph
form
inhibitor
recogn
substrat
hcv
incorpor
grow
rna
strand
result
immedi
chain
termin
one
advantag
cmethylnucleosid
lack
crossresist
associ
presenc
mutat
uridin
analog
counterpart
inact
replicon
assay
due
lack
intracellular
phosphoryl
howev
form
cytidin
uridin
analog
equal
potent
chain
termin
hcv
pharmacokinet
properti
azidocytidin
improv
triester
prodrug
balapiravir
figur
achiev
log
reduct
viral
rna
highest
dose
phase
monotherapi
clinic
trial
four
week
treatment
balapiravir
combin
viru
replic
anim
plant
soc
result
decreas
viral
load
also
hematolog
advers
event
lymphopenia
led
discontinu
develop
balapiravir
hcv
infect
analog
balapiravir
similar
modif
scaffold
also
report
none
progress
develop
recent
shown
azidoctp
good
substrat
human
mitochondri
rna
polymeras
one
protein
consid
respons
mitochondri
toxic
sever
ribonucleosid
third
major
class
nucleosid
analog
cmethyl
modif
includ
sofosbuvir
doubl
substitut
posit
ribos
evolv
earlier
cmethyl
scaffold
combin
chang
result
observ
fluorocytidin
weakli
activ
hcv
replicon
compar
fluoro
monosubstitut
counterpart
cmethylcytidin
significantli
potent
hcv
replicon
assay
less
toxic
hepatocarcinoma
cell
vitro
parent
cmethylcytidin
nucleosid
also
develop
oral
bioavail
diisobutyr
ester
prodrug
mericitabin
current
phase
ii
clinic
develop
import
seri
experi
found
cmethylcytidin
metabol
also
uridin
triphosph
form
result
intracellular
deamin
parent
uridin
analog
readili
convert
monophosph
form
intracellular
kinas
seri
monophosph
form
cmethyluridin
design
bypass
first
limit
kinas
step
phosphoramid
prodrug
made
mask
charg
alphaphosph
amino
acid
ester
aryl
group
protect
group
remov
cytoplasm
hepatocyt
cell
penetr
optim
leav
group
prodrug
separ
stereoisom
led
select
sofosbuvir
one
potent
select
inhibitor
seri
figur
addit
form
high
level
nucleosid
triphosph
ntp
exquisit
potenc
sofosbuvir
explain
vitro
fact
activ
form
cmethyluridin
effici
substrat
chain
termin
hcv
figur
studi
also
show
fluoro
substitut
contribut
less
chain
termin
cmethyl
moieti
ntp
deriv
sofosbuvir
poor
substrat
human
mitochondri
rna
polymeras
one
protein
consid
respons
mitochondri
toxic
sever
ribonucleosid
similar
two
former
class
inhibitor
mani
cmethylnucleosid
evalu
includ
potent
monophosph
guanosin
analog
progress
phase
ii
clinic
trial
discontinu
due
elev
alanin
aminotransferas
level
see
complet
review
recent
hcv
nucleosid
nucleotid
develop
quest
structur
novel
nucleosid
inhibitor
hcv
continu
activ
area
pharmaceut
research
chemic
scaffold
recent
discov
eg
date
none
class
nucleosid
analog
advanc
beyond
phase
ii
clinic
trial
sever
import
sometim
sever
human
diseas
caus
rna
virus
flavivirida
picornavirida
calicivirida
coronavirida
famili
virus
contain
positivestrand
rna
genom
rnadepend
rna
polymeras
share
signific
amino
acid
similar
base
sequenc
align
phylogenet
analysi
sinc
hcv
belong
flavivirida
famili
nucleosid
analog
origin
develop
hcv
would
also
expect
inhibit
relat
pathogen
within
famili
even
virus
positivestrand
rna
famili
predict
confirm
counterscreen
antihcv
molecul
repres
panel
virus
famili
subfamili
tabl
particular
cmodifi
nucleosid
known
inhibit
multipl
positivestrand
rna
viru
famili
one
first
report
exampl
cmethylcytidin
found
potent
cellbas
vitro
assay
flavivirus
west
nile
yellow
fever
dengu
viru
result
entir
surpris
sinc
molecul
alreadi
known
inhibit
bvdv
also
belong
flavivirida
famili
use
surrog
hcv
antivir
screen
vivo
efficaci
model
cmethylcytidin
protect
hamster
challeng
lethal
dose
yellow
fever
viru
even
administ
day
postinfect
cytidin
analog
also
inhibit
vitro
replic
tickborn
hemorrhag
feverassoci
flavivirus
addit
cmethylcytidin
inhibit
replic
norwalk
viru
footandmouth
diseas
viru
calicivirida
picornavirida
famili
respect
although
extens
profil
purin
analog
cmethyladenosin
similarli
display
broad
antivir
activ
positivestrand
rna
virus
inact
singlestrand
negativesens
rna
virus
broad
spectrum
activ
profil
chemic
relat
cethynyladenosin
although
found
also
inhibit
hcv
molecul
potent
enough
develop
specif
dengu
viru
infect
date
viru
replic
anim
plant
tabl
inhibit
positivestrand
rna
virus
nucleosid
analog
nucleosid
analog
known
inhibit
dengu
viru
replic
mous
efficaci
model
howev
safeti
profil
insuffici
enabl
drug
develop
toward
human
clinic
trial
basi
find
azido
cytidin
potent
dengu
viru
replic
vitro
ester
prodrug
balipiravir
also
repurpos
toward
treatment
dengu
viru
infect
reason
remain
clarifi
drug
reduc
either
viral
load
symptom
administ
hospit
dengueinfect
patient
challeng
discov
novel
nucleosid
analog
target
positivestrand
rna
virus
hcv
although
mani
antihcv
nucleosid
analog
may
potenti
inhibit
positivestrand
rna
virus
vitro
current
obviou
drug
candid
direct
repurpos
hcv
infect
diseas
indic
particular
sofosbuvir
fdaapprov
antihcv
nucleotid
analog
phosphoramid
prodrug
optim
specif
deliv
high
level
nucleosid
triphosph
activ
speci
releas
prodrug
moieti
firstpass
effect
process
drug
get
metabol
liver
reach
system
circul
therefor
activ
metabolit
sofosbuvir
like
significantli
distribut
organ
tissu
liver
target
positivestrand
rna
virus
comparison
cmethylcytidin
cethynyladenosin
among
known
broadspectrum
nucleosid
analog
potenti
system
organ
exposur
monophosph
triphosph
form
level
suffici
achiev
vivo
efficaci
howev
rel
poor
safeti
profil
narrow
dose
margin
make
poor
candid
clinic
develop
main
challeng
design
optim
new
inhibitor
nonhcv
positivestrand
rna
virus
search
molecul
hamper
sever
factor
first
one
need
achiev
vivo
pharmacokinet
properti
compat
deliveri
ntp
site
infect
differ
viru
includ
exampl
gi
tract
norwalk
viru
lung
rhinoviru
middl
east
respiratori
syndrom
viru
brain
west
nile
viru
lymphoid
organ
dengu
viru
mention
organspecif
prodrug
success
develop
date
nucleosid
target
liver
like
use
nonliv
infect
second
import
limit
find
new
nucleosid
analog
also
relat
triphosph
format
choic
immort
cell
line
use
vitro
infect
experi
metabol
kinas
activ
pathway
mani
common
laboratori
strain
speci
cell
line
differ
natur
human
tissu
human
primari
cell
although
gener
problem
small
molecul
drug
test
metabol
activ
nucleosid
analog
ntp
entir
reli
presenc
specif
nucleosid
nucleotid
kinas
sometim
defici
common
labadapt
cell
line
final
import
thoroughli
assess
select
toxic
new
nucleosid
analog
ensur
interfer
cellular
mechan
efficaci
dose
case
acut
infect
safeti
requir
shortterm
treatment
may
differ
antihcv
nucleotid
despit
challeng
prospect
use
nucleosid
analog
treat
acut
infect
caus
rna
virus
repres
import
paradigm
shift
new
frontier
futur
antivir
therapi
lesburg
ca
cabl
mb
ferrari
e
hong
z
mannarino
af
et
al
crystal
structur
rnadepend
rna
polymeras
hepat
c
viru
reveal
fulli
encircl
activ
site
nat
struct
biol
togeth
bressanelli
et
al
studi
report
first
crystal
structur
hcv
show
polymeras
close
finger
conform
serv
encircl
enzym
activ
site
